Sneha Ashok Shah, Presenter: Nothing to Disclose

Nilendu Chandrakant Purandare DMRD, Abstract Co-Author: Nothing to Disclose

Archi Agrawal MBBS, Abstract Co-Author: Nothing to Disclose

Seema A. Medhi DMRD, Abstract Co-Author: Nothing to Disclose

Venkatesh Rangarajan MBBS, Abstract Co-Author: Nothing to Disclose

Chaitali Bongulwar MBBS, Abstract Co-Author: Nothing to Disclose

Role of FDG PET/CECT in pre surgical staging of Neuroblastomas. Demonstrate utility of Radionuclide Imaging in treatment response assessment and dilemmas Explore the complex biology of Neuroblastoma using different receptor expression and its future use in therapeutics.  

18 F FDG PET/CECT in neuroblastomas - As image guided risk factor in presurgical staging (INRGSS) - Comparison with 131 I MIBG & incremental value. - Complementary role in response assessment along with 131 - I MIBG - Utility in Restaging  Understand complex tumor biology of Neuroblastoma -  radionuclide imaging to identify expression of somatostatin, GLUT & nor epinephrine. Use of phenotype information for therapeutics in future.  

http://abstract.rsna.org/uploads/2014/14010108/14010108_xmij.pdf

Shah, S, Purandare, N, Agrawal, A, Medhi, S, Rangarajan, V, Bongulwar, C, Biological Characterization of Neuroblastomas Using 18 F FDG PET/CT, 131 -I MIBG and Somatostatin Receptor Imaging and Its Role in Presurgical Staging and Management.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14010108.html